who we are

Innovicto is a consultancy firm offering strategic solutions for clinical due diligence, clinical development, medical affairs and clinical project management.

We collaborate with investors, biopharmaceutical companies, pharmaceutical companies and academic institutions, enabling the development and execution of clinical development programs and the excellence in medical affairs and project managment across Asia and worldwide.

We are committed to provide top-tier services to our clients, leveraging the expertise of our professionals who possess extensive knowledge in clinical research, medical affairs and project management.

We specialise in oncology area and help our clients provide the solutions to make informed decisions about their product development.

enquires

2 + 1 =

click here to arrange an appointment

 

Our Team

Dr. Aung Myo

CEO & Principal Consultant

Dr. Aung Myo, MD, MSc is a medical oncologist with over 17 years of experience in clinical development and medical affairs within the pharmaceutical and biotech industries, including tenures at GSK, MSD, and Tessa Therapeutic. As a senior leader, he has successfully formulated clinical development plans and designed and implemented global and regional phase 1-3 clinical trials. He played a pivotal role in the medical affairs strategy for the successful launch of Keytruda (pembrolizumab) across various indications in the Asia Pacific region. His expertise spans safety and pharmacovigilance, tumor marker studies, and regulatory activities.
Aung’s deep knowledge of oncology disease areas and treatment modalities is complemented by his core competencies, including clinical strategies and development planning, clinical trial oversight, authoring key clinical documents, medical monitoring, product development, regulatory affairs, medical affairs planning, scientific exchange, data gap identification, evidence generation, and organizational leadership. His extensive experience covers the Asia Pacific, China, Japan, India, and the US.
Aung was a clinical fellow in the Haemato-Oncology department at the National University Hospital, Singapore. He has also served on the Advisory Group for the National Healthcare Group Clinical Trial Committee (NCTC) in Singapore.

Greg Bewick

Senior Consultant

With over two decades of global leadership experience, Greg has excelled in the pharmaceutical, healthcare and manufacturing domain.

Renowned for his expertise in New Product Development (NPD) using the Stage-Gate framework, Greg has successfully established and managed multiple Project Management Offices (PMOs) Globally and in particular Europe & Asia Pacific. America.

His strategic oversight and alignment of projects with C-Suite strategy have driven transformative changes, particularly in integrating R&D/Product Innovation into market launch. A key project was globally rolling out a CTMS (Clinical Trial Management Systems), improving clinical trial processes, particularly in regard to Project Management of trials across Asia and contributing to the successful launch of vaccines.

Greg’s qualifications include an MBA from Birmingham University Business School, Advanced Project Management Certification from Stanford University, and several practitioner-level credentials in Project and Change Management.

His leadership in project governance, risk management, and continuous improvement has consistently delivered high-impact results and multimillion-dollar benefits.

Jessica Cordes

Senior Consultant

Jessica Cordes is a highly skilled and experienced Clinical Operations leader with a focus in early clinical trials in oncology. She has a strong background in molecular life science and has worked for leading companies in the pharmaceutical and biotech industry, managing clinical trials from phase I to IV in various indications.

She has demonstrated her ability to oversee complex and innovative clinical trials, such as a monoclonal antibody in multiple myeloma at MorphoSys, a cell and gene therapy in a hemato-oncology basket at Medigene, and a combination of cell and gene therapy and bispecific antibodies in solid tumors at Immatics. She has also shown her leadership and strategic vision in building and leading global clinical operations teams, guiding the operational strategy for clinical trials, and ensuring high-quality standards as well as regulatory compliance.

Since 2023, she has been sharing her expertise and insights as a Senior Consultant and Trainer in her own company Clinical Excellence GmbH, providing clinical due diligence and strategic solutions for investors, pharma and biotech companies.

Tracy Thia

Senior Consultant

With over two decades in the clinical research industry, Tracy Thia brings extensive expertise in Clinical Project Management and Clinical Operations. Her career spans leadership roles at major pharmaceutical companies, global CROs, and biotech firms, including Merck Healthcare KGaA, MSD, Syneos, iQVIA, and Tessa Therapeutics. Tracy’s experience covers a broad range of therapeutic areas, such as oncology, ophthalmology, fertility, respiratory, neurology, and cardiology, enabling her to provide innovative solutions to complex clinical research challenges. She has managed Phase I to IV clinical trials, with recent focus on late-phase/phase IV studies, peri-approval clinical programs, and CAR-T development program management. Tracy is a certified Project Management Professional (PMP) and holds a MSC in Clinical Research and an Executive MBA.
Based in Singapore, Tracy specializes in the APAC region, offering strategic guidance and deep insights into this diverse market. Beyond regional boundaries, her notable achievements include leading the set-up of global rare disease registries, and directing early access programs across 40 countries. Tracy excels in streamlining workflows, optimizing processes, and has spearheaded global operational excellence initiatives, significantly enhancing trial efficiency and outcomes. Her global mindset and APAC regional expertise, coupled with her deep understanding of cultural nuances, make her an ideal partner for companies seeking to enter and succeed in the APAC market.

Dr. Ling Claytor

Senior Consultant

Dr. Ling Claytor, MD, PhD, is a seasoned expert in pediatric cardiology with over 15 years of experience in the pharmaceutical, biotech, medical devices and nutritional industries, complemented by more than a decade of clinical service, teaching, and academic research. She earned her medical degree and PhD from The University of Hong Kong, followed by post-doctoral and professional training at Oregon Health and Science University in the U.S. Dr. Claytor also holds two Master’s degrees in Biochemistry and Rehabilitation Sciences.

In her career, Dr. Claytor has held numerous leadership positions. She was Global Medical Lead in Emergent BioSolutions and served as the Medical Director for Abbott Nutrition in Asia Pacific, where she led a team of medical professionals dedicated to advancing nutritional innovations for diverse populations. Prior to Abbott, she was the Medical Director at Roche, overseeing medical affairs, clinical operations, regulatory affairs, pharmacovigilance, logistics quality, and medical compliance. Her career also includes significant roles at GlaxoSmithKline (GSK) and Bayer.

Dr. Claytor’s research background includes cardiology research with a focus on medical imaging. She completed her post-doctoral training under the guidance of the renowned Pediatric Cardiologist Prof. David Sahn at Oregon Health and Science University, managing FDA-compliant research projects and collaborating with industry leaders such as GE, Philips, and Siemens. Her scholarly contributions include chapters in medical textbooks and numerous peer-reviewed publications, along with presentations at prominent conferences like AHA and ACC.

Currently based in Singapore, Dr. Claytor brings extensive international experience from her work in Hong Kong, the U.S., and Singapore, making her a valuable asset in her new role as a Senior Consultant at Innovicto.